Andere Kunden interessierten sich auch für
![Interleukin-1 Receptor Antagonist in Knee Osteoarthritis]( "Interleukin-1 Receptor Antagonist in Knee Osteoarthritis")
Interleukin-1 Receptor Antagonist in Knee Osteoarthritis42,99 €![Triptolide as a potential aryl hydrocarbon receptor antagonist]( "Triptolide as a potential aryl hydrocarbon receptor antagonist")
Triptolide as a potential aryl hydrocarbon receptor antagonist35,99 €![Transferrin Receptor]( "Transferrin Receptor")
Transferrin Receptor29,99 €![Tumor Necrosis Factor Receptor]( "Tumor Necrosis Factor Receptor")
Tumor Necrosis Factor Receptor22,99 €![Effects of a BMP Antagonist on Fracture Healing in a Mouse Model]( "Effects of a BMP Antagonist on Fracture Healing in a Mouse Model")
Effects of a BMP Antagonist on Fracture Healing in a Mouse Model23,99 €![5-HT3 antagonist]( "5-HT3 antagonist")
5-HT3 antagonist32,99 €![High Glucose Regulation of Human Vascular Thrombin Receptor PAR-4]( "High Glucose Regulation of Human Vascular Thrombin Receptor PAR-4")
High Glucose Regulation of Human Vascular Thrombin Receptor PAR-439,99 €
Please note that the content of this book primarily consists of articles available from Wikipedia or other free sources online. Neurokinin 1 (NK1) antagonists are a novel class of medications that possesses unique antidepressant, anxiolytic, and antiemetic properties. The discovery of neurokinin 1 (NK1) receptor antagonists was a turning point in the prevention of nausea and vomiting associated with cancer chemotherapy. An example of a drug in this class is aprepitant. Chemotherapy-induced emesis appears to consist of acute and delayed phases. So far the acute phase emesis responds to 5-HT3 antagonists while the delayed phase remains difficult to control. The discovery and development of NK1 receptor antagonists have elicited antiemetic effect in both acute and especially in delayed phases of emesis.